Item 8.01 Other Events

On January 4, 2022, Zynerba Pharmaceuticals, Inc. (the "Company") issued a press release announcing clinical development updates for Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome and developmental and epileptic encephalopathies. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Attached as Exhibit 99.2 is a presentation that the Company will post on its website on January 4, 2022 and may use from time to time in presentations or discussions with investors, analysts or other parties.

Item 9.01 Financial Statements and Exhibits






(d) Exhibits



Exhibit
No.                                       Document

  99.1       Press Release, dated January 4, 2022

  99.2       Zynerba Pharmaceuticals, Inc. Presentation

104        The cover page from this current report on Form 8-K, formatted in
           Inline XBRL

© Edgar Online, source Glimpses